Takeda launches narcolepsy pill in US
Takeda has launched its new narcolepsy treatment in the United States following clearance from the Drug Enforcement Administration. Orzeyful targets the underlying cause of the rare sleep disorder and is priced at $16500 per bottle.
Xurve View
Insights:
Xurve View
TAKEDA PHARMACEUTICAL CO LTD launched its narcolepsy pill in the United States on Thursday after a regulatory decision cleared the final hurdle. The rollout marks the first treatment to target the underlying biological cause of the rare sleep disorder. The launch gives the Japan-based drugmaker immediate access to a market of 120,000 patients nationwide.
